290 related articles for article (PubMed ID: 33841751)
1. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.
Kumar S; Singh B; Kumari P; Kumar PV; Agnihotri G; Khan S; Kant Beuria T; Syed GH; Dixit A
Comput Struct Biotechnol J; 2021; 19():1998-2017. PubMed ID: 33841751
[TBL] [Abstract][Full Text] [Related]
2. Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.
Khan MF; Ansari WA; Ahamad T; Khan MA; Khan ZA; Sarfraz A; Khan MA
J Mol Model; 2022 Jul; 28(8):212. PubMed ID: 35794497
[TBL] [Abstract][Full Text] [Related]
3. Structural Similarity of SARS-CoV2 M
Bafna K; Krug RM; Montelione GT
ChemRxiv; 2020 Apr; ():. PubMed ID: 32511291
[TBL] [Abstract][Full Text] [Related]
4. Polypharmacology guided drug repositioning approach for SARS-CoV2.
Jamir E; Sarma H; Priyadarsinee L; Kiewhuo K; Nagamani S; Sastry GN
PLoS One; 2023; 18(8):e0289890. PubMed ID: 37556478
[TBL] [Abstract][Full Text] [Related]
5. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.
Ortega JT; Serrano ML; Jastrzebska B
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32599963
[TBL] [Abstract][Full Text] [Related]
6. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
[TBL] [Abstract][Full Text] [Related]
7. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
[TBL] [Abstract][Full Text] [Related]
8. Drugs repurposing against SARS-CoV2 and the new variant B.1.1.7 (alpha strain) targeting the spike protein: molecular docking and simulation studies.
Pande M; Kundu D; Srivastava R
Heliyon; 2021 Aug; 7(8):e07803. PubMed ID: 34423145
[TBL] [Abstract][Full Text] [Related]
9. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
10. Applying polypharmacology approach for drug repurposing for SARS-CoV2.
Jamir E; Sarma H; Priyadarsinee L; Nagamani S; Kiewhuo K; Gaur AS; Rawal RK; Murugan NA; Subramanian V; Sastry GN
J Chem Sci (Bangalore); 2022; 134(2):57. PubMed ID: 35498548
[TBL] [Abstract][Full Text] [Related]
11. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
Tammam SN; El Safy S; Ramadan S; Arjune S; Krakor E; Mathur S
J Control Release; 2021 Sep; 337():258-284. PubMed ID: 34293319
[TBL] [Abstract][Full Text] [Related]
12. Virtual repurposing of ursodeoxycholate and chenodeoxycholate as lead candidates against SARS-Cov2-Envelope protein: A molecular dynamics investigation.
Yadav R; Choudhury C; Kumar Y; Bhatia A
J Biomol Struct Dyn; 2022 Jul; 40(11):5147-5158. PubMed ID: 33382021
[TBL] [Abstract][Full Text] [Related]
13. In silico strategies to identify protein-protein interaction modulator in cell-to-cell transmission of SARS CoV2.
Basu A; Sarkar A; Bandyopadhyay S; Maulik U
Transbound Emerg Dis; 2022 Nov; 69(6):3896-3905. PubMed ID: 36379049
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
Iftikhar H; Ali HN; Farooq S; Naveed H; Shahzad-Ul-Hussan S
Comput Biol Med; 2020 Jul; 122():103848. PubMed ID: 32658735
[TBL] [Abstract][Full Text] [Related]
15. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase.
White MA; Lin W; Cheng X
bioRxiv; 2020 Aug; ():. PubMed ID: 32817950
[TBL] [Abstract][Full Text] [Related]
16. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.
Peele KA; Kumar V; Parate S; Srirama K; Lee KW; Venkateswarulu TC
J Pharm Sci; 2021 Jun; 110(6):2346-2354. PubMed ID: 33684397
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
18. Targeting SARS CoV2 (Indian isolate) genome with miRNA: An in silico study.
Devi A; Chaitanya NSN
IUBMB Life; 2020 Nov; 72(11):2454-2468. PubMed ID: 32909697
[TBL] [Abstract][Full Text] [Related]
19. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
Chandra A; Gurjar V; Ahmed MZ; Alqahtani AS; Qamar I; Singh N
J Biomol Struct Dyn; 2022 Aug; 40(12):5507-5514. PubMed ID: 33491573
[TBL] [Abstract][Full Text] [Related]
20. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
